Floatz Rating
B63/100
Confidence
Indicative
Sponsor
GlaxoSmithKline
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07286266CT.gov A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | — | Not Yet Recruiting | — | — | — |
NCT07213804CT.gov A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer | — | Recruiting | — | — | — |
NCT05613088CT.gov A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT02903004CT.gov Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients | — | Completed | — | — | — |
NCT02487095CT.gov Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | — | Completed | — | — | — |
NCT01121406CT.gov BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | — | Completed | — | — | — |
NCT00231855CT.gov Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers | — | Completed | — | — | — |
NCT00057720CT.gov TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nogitecan (this asset) | GlaxoSmithKline | P3 | B · 63 |
| Adriamycin | GlaxoSmithKline | P4 | BBB |
| Carboplatin | Eli Lilly and Company | P3 | BB |
| Pazopanib | The Christie NHS Foundation Trust | P2 | BB |
| Canfosfamide | Telik | P3 | BB |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | BB |
| Niraparib | GlaxoSmithKline | P4 | BB |
| Trabectedin | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Merck Sharp & Dohme LLC | P3 | B |
+42 more in the Ovarian Neoplasm cohort
Other indications for Nogitecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | BBB · 74 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Non-Small Cell Lung Carcinoma | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nogitecan in Ovarian Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/nogitecan-ovarian-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →